Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-322525

ABSTRACT

Background: Serosurvalence is crucial in estimating the range of SARS-CoV-2 infections, predicting the possibility of another wave, and decide on a vaccination strategy. To understand the herd immunity after the COVID-19 pandemic, the seroprevalence was measured in 3062 individuals with or without COVID-19. Methods: : The levels of SARS-CoV-2 antibody IgM and IgG were measured by the immuno-colloidal gold method. Results: : The mean seroprevalence for IgM and IgG in all participants was 2.81% and 7.51%, respectively. The positive rate of IgG was significantly higher in women than in men (P<0.05). The highest positive rate of IgM was observed in 41-60 years of age (3.49%), while the highest seroprevalence for IgG was observed in persons >60 years of age (8.61%). The positive rates of IgM and IgG in the convalescent patients were 31.82% and 77.27%, respectively, which was significantly higher than individuals with suspected syndromes or individuals without any clinical signs (P<0.01). Seroprevalence for IgG in medical staff was markedly higher than those in residents. The seroprevalence in patients with various comorbidity was no significant difference (P>0.05). Conclusions: : The low positive rate of the SARS-CoV-2 IgM and NA test indicated that the SARS-CoV-2 outbreak is subsiding after three months, and the possibility of reintroduction of the virus from an unidentified natural reservoir is low. Seroprevalence provides the information for humoral immunity and vaccine in the future.

2.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-313420

ABSTRACT

Aim: Exosomes are frequently used for characterization of diseases, e.g., viral infections, but have not been reported for COVID-19. The aims of our study were to determine exosomes’ novel applications for SARS-CoV-2 RNA infection and prognosis of COVID-19 disease.Methods: From 15 COVID-19 patients and five healthy controls, 32 serum samples were collected by clinicians in Wuhan, China. Exosomes were purified, their RNAs (exoRNAs) were isolated and analyzed using RT-PCR for the presence of the N and/or ORF1ab viral genes, and the human RNaseP gene as reference.Results: Exosomes showed their typical lipid bilayer structure between 30 to 150 nm in size. No viral RNAs were detected from the 5 healthy controls. From 4 patients (26.67% of the patients), only the viral N but not the ORF1ab genes was detected. However, intact viral particles were not observed in exosome samples from the four positive patients. Importantly, expression of the N gene was detected during the active or early-stages of the disease, and the expression levels gradually decreased from the critical to the mild patients (in reverse to their CT values): Patient 1 /critical/ progress/ (CT-value: 34.74), Patient 9/severe/progress (CT-value: 37.65), Patient 11/severe /progress (CT-value: 37.16), and Patient 15/mild/early stage (CT-value: 38.44). Among them, only patient 1 had received stem cell transfusion. Patients 9 and 11 demonstrated recurrence of SARS-CoV-2. Patient 15 was the earliest phase patient with the N gene.Conclusion: SARS-CoV-2 RNAs were detected in exosomes which came only from the 15 COVID-19 patients but not from the 5 healthy controls. In addition, the presence of the viral N gene showed association with severity in the disease. Our novel discovery indicates that SARS-CoV-2 RNAs in serum exosomes can be used to complement existing assays for characterization of the SARS-CoV-2 infection and for prognosis of the COVID-19 disease.Funding Statement: This study was funded by National Natural Science Foundation of China (Grant No. 81702273), the Key Project for Anti-2019 Novel Coronavirus Pneumonia from the National Key Research and Development Program of China (Grant No. 2020YFC0845500), the National Key Research and Development Program of China (Grant No. 2018YFE0204500), Science and technology key project of Guangdong Province: Study on the source and epidemiology of COVID-19 (No.2020B111107001), the Scientific research project of COVID-19 epidemic prevention and control in Guangdong universities (No.2020KZDZX1087), and the Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund, Project znpy2018117 and znpy2019064.Declaration of Interests: We declare no competing interests.Ethics Approval Statement: The study was reviewed and approved by Medical Ethics Committee Zhongnan Hospital of Wuhan University in the Scientific Research project No 2020066.

3.
BMC Infect Dis ; 22(1): 10, 2022 Jan 04.
Article in English | MEDLINE | ID: covidwho-1608186

ABSTRACT

BACKGROUND: Serosurveillance is crucial in estimating the range of SARS-CoV-2 infections, predicting the possibility of another wave, and deciding on a vaccination strategy. To understand the herd immunity after the COVID-19 pandemic, the seroprevalence was measured in 3062 individuals with or without COVID-19 from the clinic. METHODS: The levels of SARS-CoV-2 antibody IgM and IgG were measured by the immuno-colloidal gold method. A fusion fragment of nucleocapsid and spike protein was detected by a qualitative test kit with sensitivity (89%) and specificity (98%). RESULTS: The seroprevalence rate for IgM and IgG in all outpatients was 2.81% and 7.51%, respectively. The sex-related prevalence rate of IgG was significantly higher (P < 0.05) in women than men. The highest positive rate of IgM was observed in individuals < 20 years of age (3.57%), while the highest seroprevalence for IgG was observed in persons > 60 years of age (8.61%). Positive rates of IgM and IgG in the convalescent patients were 31.82% and 77.27%, respectively, which was significantly higher than individuals with suspected syndromes or individuals without any clinical signs (P < 0.01). Seroprevalence for IgG in medical staff was markedly higher than those in residents. No significant difference of seroprevalence was found among patients with different comorbidities (P > 0.05). CONCLUSIONS: The low positive rate of the SARS-CoV-2 IgM and nucleic acid (NA) test indicated that the SARS-CoV-2 outbreak is subsiding after 3 months, and the possibility of reintroduction of the virus from an unidentified natural reservoir is low. Seroprevalence provides information for humoral immunity and vaccine in the future.


Subject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Viral , Communicable Disease Control , Female , Humans , Immunoglobulin G , Immunoglobulin M , Male , Pandemics , Seroepidemiologic Studies
4.
Cytokine ; 143: 155523, 2021 07.
Article in English | MEDLINE | ID: covidwho-1163610

ABSTRACT

Cytokines play pleiotropic, antagonistic, and collaborative in viral disease. The high morbidity and mortality of coronavirus disease 2019 (COVID-19) make it a significant threat to global public health. Elucidating its pathogenesis is essential to finding effective therapy. A retrospective study was conducted on 71 patients hospitalized with COVID-19. Data on cytokines, T lymphocytes, and other clinical and laboratory characteristics were collected from patients with variable disease severity. The effects of cytokines on the overall survival (OS) and event-free survival (EFS) of patients were analyzed. The critically severe and severe patients had higher infection indexes and significant multiple organ function abnormalities than the mild patients (P < 0.05). IL-6 and IL-10 were significantly higher in the critically severe patients than in the severe and mild patients (P < 0.05). IL-6 and IL-10 were closely associated with white blood cells, neutrophils, T lymphocyte subsets, D-D dimer, blood urea nitrogen, complement C1q, procalcitonin C-reactive protein. Moreover, the IL-6 and IL-10 levels were closely correlated to dyspnea and dizziness (P < 0.05). The patients with higher IL-10 levels had shorter OS than the group with lower levels (P < 0.05). The older patients with higher levels of single IL-6 or IL-10 tended to have shorter EFS (P < 0.05), while the patients who had more elevated IL-6 and IL-10 had shorter OS (P < 0.05). The Cox proportional hazard model revealed that IL-6 was the independent factor affecting EFS. IL-6 and IL-10 play crucial roles in COVID-19 prognosis.


Subject(s)
COVID-19/blood , COVID-19/pathology , Interleukin-10/blood , Interleukin-6/blood , T-Lymphocyte Subsets/immunology , Adult , Age Factors , Aged , Aging , Blood Coagulation Factors/analysis , COVID-19/mortality , COVID-19/therapy , Cytokine Release Syndrome/pathology , Female , Humans , Lymphocyte Count , Male , Middle Aged , Retrospective Studies , SARS-CoV-2/immunology , Severity of Illness Index , Survival Analysis , T-Lymphocyte Subsets/cytology , Thromboembolism/pathology , Treatment Outcome
5.
J Inflamm Res ; 13: 773-787, 2020.
Article in English | MEDLINE | ID: covidwho-1044351

ABSTRACT

PURPOSE: It is difficult to predict the prognosis of COVID-19 patients at the disease onset. This study was designed to add new biomarkers into conventional inflammatory panels to build an optimal combination panel, to better triage patients and predict their outcomes. PATIENTS AND METHODS: Biochemical parameters representing multi-organ functions, cytokines, acute-phase proteins, and other inflammatory markers were measured in COVID-19 patients on hospital admission. Receiver operating characteristic (ROC) curves, logistic regression, event-free survival (EFS), and Cox analyses were performed to screen and compare the predictive capabilities of the new panel in patients with different illness severity and outcome. RESULTS: This study included 120 patients with COVID-19, consisting of 32 critical, 28 severe, and 60 mild/moderate patients. Initial levels of the selected biomarkers showed a significant difference in the three groups, all of which influenced patient outcome and EFS to varying degrees. Cox proportional hazard model revealed that procalcitonin (PCT) and interleukin 10 (IL-10) were independent risk factors, while superoxide dismutase (SOD) was an independent protective factor influencing EFS. In discriminating the critical and mild patients, a panel combining PCT, IL-6, and neutrophil (NEUT) yielded the best diagnostic performance with an AUC of 0.99, the sensitivity of 90.60% and specificity of 100%. In distinguishing between severe and mild patients, SOD's AUC of 0.89 was higher than any other single biomarker. In differentiating the critical and severe patients, the combination of white blood cell count (WBC), PCT, IL-6, IL-10, and SOD achieved the highest AUC of 0.95 with a sensitivity of 75.00% and specificity of 100%. CONCLUSION: The optimal combination panel has a substantial potential to better triage COVID-19 patients on admission. Better triage of patients will benefit the rational use of medical resources.

6.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-1238

ABSTRACT

Objective: Sero-surveillance was conducted in the patients with or without COVID-19. brbrMethods: Sera were collected from 3062 patients of Wuhan, and the

SELECTION OF CITATIONS
SEARCH DETAIL